Specialty Pharmacy

Top news of the day across the health care landscape.

Foreign-born black women aren’t benefiting from HIV prevention programs at the same rates as other women.

Prucalopride (Motegrity, Shire) is the only serotonin-4 receptor agonist approved for adults with chronic idiopathic constipation.

Specialty pharmacy stakeholders must strike a delicate balance between cost concerns and health outcomes, while keeping the patient at the center.

Top news of the day across the health care landscape.

Patients administered guselkumab achieved an improvement of 90% or more Psoriasis Area Severity Index score than those administered secukinumab.

AMD will affect more than 200 million people globally by 2020 and has become the leading cause of blindness in developed countries.

Two pharmacist groups jointly filed a motion urging the federal judge to block CVS and Aetna from further integration while the potential negative effects are assessed.

Slow-growing gliomas in patients with neurofibromatosis type 1 may be vulnerable to immunotherapy.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the increasing cost burden of cancer therapies and future strategies for mitigating costs.

Top news of the day across the health care landscape.

Study highlights the importance of testing and early intervention in young patients with hepatitis C virus.

Fentanyl, heroin, hydrocodone, and methamphetamine among the most frequently mentioned drugs connected to overdoses, according to a new report from the CDC.

The FDA has approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to trastuzumab (Herceptin, Genentech) for the treatment of HER2-overexpressing breast cancer. 

Romiplostim (NPLATE, Amgen) approved for the treatment of pediatric patients with immune thrombocytopenia who have had an insufficient response to other therapies.

Updated data from the HAVEN 2 study showed that the majority of children treated with emiciziumab-kxwh (Hemlibra, Genentech) experienced sustained bleed control.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

A recent study found further evidence that hepatitis C reinfection rates are greater in drug users despite successful treatment with direct-acting antiviral therapy.

Understanding how HIV-related stigma can affect patients later in life can lead to new approaches to address cognitive impairment in this population.

Abaloparatide and teriparatide are the only anabolic agents approved by the FDA for women with osteoporosis at high-risk of fragility fractures.

Top news of the day across the health care landscape.

Emerging platforms make it feasible for hepatitis C testing to be conducted in settings that within or outside of health care facilities, such as prisons.

SUBA-itraconazole is indicated for the treatment of blastomycosis, pulmonary and extrapulmonary; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis; and aspergillosis, pulmonary and extrapulmonary.

A patient-centric approach is vital to effective specialty pharmacy services.

Study shows that routinely screening inmates for hepatitis C virus at entry may identify a significant number of cases that would have been missed through targeted testing.

Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, talks about new therapies for hemophilia and exciting advancements on the horizon.

Top news of the day across the health care landscape

Experts argue whether a decline in cognitive function should lead to a change in disease-modifying therapy for multiple sclerosis.